Clinical stage biotechnology company Adicet Bio Inc (Nasdaq: ACET) announced on Wednesday that it has received FDA approval to amend its Investigational New Drug (IND) application to include idiopathic inflammatory myopathy (IIM) and stiff person syndrome (SPS) in its ongoing Phase 1 trial for ADI-001.
Patient enrollment for these cohorts is set to begin in the first quarter of 2025. ADI-001's clinical development now targets six autoimmune diseases, including lupus nephritis (LN), systemic lupus erythematosus (SLE), systemic sclerosis (SSc) and anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV).
Adicet plans to report initial data from its Phase 1 trial in the first half of 2025.
Amgen updates on data for MariTide
argenx and Zai Lab secure Chinese approval for VYVGART Hytrulo for CIDP
Faron Pharmaceuticals files patent for soluble Clever-1 in autoimmune disease treatment
AstraZeneca's Tezspire achieves positive results in nasal polyps trial
OSE Immunotherapeutics' Lusvertikimab shows promise in ulcerative colitis
Formosa Pharmaceuticals signs licensing agreement with DÁVI Farmaceutica
GlycoMimetics to combine with Crescent Biopharma
Lilly's mirikizumab shows sustained efficacy in IBD
EydisBio receives USD0.5m Phase one SBIR grant from NIH's National Institute on Aging
Redwire partners with Bristol Myers Squibb for space-based drug research
Bruker unveils USD100 deep plasma proteomics solution
Accord Healthcare wins CHMP approval for Stelara biosimilar Imuldosa
Foresee Pharmaceuticals completes linvemastat (FP-020) phase clinical study in Australia
Adicet Bio receives FDA clearance to expand ADI-001 trials to additional autoimmune diseases